Vascular closure devices in stroke patients receiving tissue plasminogen activator: A retrospective analysis from an academic tertiary medical center and a teaching community hospital stroke database

Stroke is the fourth leading cause of death in the United States [1]. Recanalization, or opening, of the blocked artery in ischemic stroke patients can limit the extent of infarction and significantly improve a patient's outcome [2]. In 1995, NINDS tPA (tissue plasminogen activator) trial suggested that tPA administered intravenously within three hours of stroke onset could improve functional outcomes in patients [3]. Since then, acute stroke therapy has been in constant evolution with the universal goals of improving outcomes and reduction in complications.
Source: Clinical Neurology and Neurosurgery - Category: Neurosurgery Authors: Source Type: research